Cardiovascular disease (CVD) is the leading cause of mortality worldwide and it is well known that end-stage renal disease (ESRD) is a profound consequence of the progression of CVD.
Introduction
mediators such as angiotensin II, endothelin and serotonin (95) . In contrast, studies in saltsensitive hypertensive animal models suggest that 20-HETE has antihypertensive and natriuretic properties (117) .
EETs are synthesized in the endothelium and are considered important vasodilatory regulators of vascular tone especially when the bioavailability of the endothelium-derived vasodilator nitric oxide is reduced (11, 56, 81) . EETs are also endothelium-derived hyperpolarizing factors (EDHFs) in a number of vascular beds, including the renal circulation (10, 57, 109). CYP epoxygenase metabolites and EETs regulate renal sodium and water excretion as indicated by increased CYP epoxygenase activity and urinary EETs excretion following excessive dietary salt intake (129) (130) . Beside antihypertensive properties, EETs have potent anti-inflammatory properties as previous studies have demonstrated that EETs decrease cytokine-induced endothelial expression of leukocyte adhesion molecules (77). EETs also have thrombolytic activity as they inhibit platelets adhesion to endothelial cells and increase tissue plasminogen activator expression (55, 78). EETs provide protective effects against vascular remodeling via inhibiting the proliferation of vascular smooth muscle cells (108) . In endothelial cells, EETs have the opposite effect as they augment cell proliferation and migration suggesting that EETs could improve atherogenesis and promote neovascularization in ischemic diseases (70, 116) . EETs also increase endothelial cell survival and attenuate apoptosis (19) (20) 68 ). The versatile effects of EETs make them a therapeutic target for end-organ damage associated with CVD (47) especially after recent reports suggest that genetic variations in the CYP epoxygenase is associated with increased risk of CVD (8, 61). Additionally, the anti-inflammatory and antihypertensive properties of EETs also make them a novel strategy to halt the progression of CVD to ESRD; however, conversion of EET epoxides to their corresponding diols (DHETs) by soluble epoxide hydrolase (sEH) enzyme limits EETs availability and decreases their beneficial cardiovascular properties.
Soluble epoxide hydrolase (sEH)
Microsomal and soluble epoxide hyprolase are two well-known epoxide hydrolase enzymes with different subcellular localization and substrate selectivity (24, 47, 128) . The microsomal epoxide hydrolase (mEH) is involved in the metabolism of environmental contaminants whereas soluble epoxide hydrolase (sEH) was initially discovered as a metabolizing enzyme for carcinogenic xenobiotics until it was later found that sEH also metabolizes EETs to less active DHETs (69, 73) . The sEH enzyme is found in many tissues such as liver, kidney, lung, heart and ovary and is localized in cytosol, microsomes and peroxisomes (66, 99) . The mammalian sEH is a ubiquitously expressed homodimeric enzyme consisting of two 62 kDa monomers (69, 73) . Each monomer has two distinct domains, the N-terminal domain with phosphatase activity and the C-terminal domain with sEH activity (26-27, 74). There are no known selective in vivo inhibitors of the N-terminal domain and current inhibitors target the Cterminal domain without affecting N-terminal domain (47). Compelling evidence in the literature using wild-type (WT) and sEH gene (Ephx2) knock-out hypertensive and diabetic mice models suggest that the phosphatase domain does not contribute to blood pressure regulation or renal injury (23, 67, 101). The human Ephx2 consists of 19 exons encoding 555 amino acids and has 73 % homology with mouse sEH protein sequences with 100 % conservation in the catalytic residues (85). Clinically, a number of polymorphisms in Ephx2 that influence sEH enzymatic activity has been recently reported in CVD suggesting that increased EETs bioavailability could have potential therapeutic benefits in CVD (9, 54, 58, 79, 85).
EETs signaling mechanisms
The cellular action of EETs involves either binding to cell surface receptors and/or their intracellular uptake and direct interaction with ion channel or transcription factors. The diverse cell-signaling mechanisms of EETs suggest that EETs may have more than one receptor.
Substantial data in the literature demonstrate that EETs bind to selective G-protein coupled receptor to initiate intracellular signaling pathways (47, 56, 105). However, this possibility needs further investigation as long as a putative EET receptor has yet to be clearly identified. EETsinduced vasodilatation and inhibition of the renal sodium-potassium ATPase are potential antihypertensive mechanisms (47, 80). EETs generated by endothelial cells dilate blood vessels via the activation of the Gα S protein, adenylate cyclase, to increase cAMP which in turn activates vascular smooth muscle cells large-conductance calcium-activated potassium channels resulting in potassium efflux from the smooth muscle cell and subsequent membrane hyperpolarization (4, 36). There is also evidence for cAMP activation of protein kinase A (PKA) and ADP ribosylation of Gsα cell signaling mechanisms in mediating EETs activation of vascular smooth muscle calcium-activated potassium channels in renal vessels (32, 48, 60). Another alternative mechanism for the EETs vasorelaxant response is the activation of vanilloid (TRP) channel to increase calcium influx leading to endothelial potassium channel activation and hyperpolarization of endothelium which could also trigger vascular smooth muscle relaxation(31, 113). Like endothelial and vascular smooth muscle cells, EETs hyperpolarize platelet cell membranes through activation of calcium-activated potassium channels (55). (108) . EETs have also shown to inhibit apoptosis via activation of PI3K/AKT pathway to inhibit extracellular signal-regulated kinase (ERK1/2) dephosphorylation (122) .
Enhancement of EETs availability in CVDs
Recent studies have shown a limited biological activity of EETs in CVD due to their rapid metabolism by sEH to DHETs or by fatty acid β-oxidation to 16-carbon epoxy derivatives (23, (114) (115) . Although the physiological properties of DHETs are not fully addressed, they have limited biological activity in comparison to EETs. Elevated EETs levels is now being considered as a new therapeutic target for the treatment of CVD as increased EETs levels protect the overall health of CVD patients from end-organ damage. There are two primary approaches to increase EETs effect in vivo. The first approach is to increase EETs survival via the inhibition of EETs degradation by sEH using sEH inhibitors. The second approach is to develop stable EETs agonists that resist auto-oxidation and metabolism by sEH enzyme. Both approaches have recently shown promising evidence in decreasing end-organ damage associated with CVD.
Cardiovascular effects of sEH inhibitors
Inhibition of sEH has been shown to provide protective effects against a variety of CVD such as hypertension, stroke, cardiac hypertrophy, diabetes and atherosclerosis as well as slow the progression of end-organ damage, endothelial dysfunction and inflammation associated with CVD (67, 80, 86, 101, 111, 126) .
In hypertension, the vasodilatory effects of sEH inhibitors were tested in vitro (51, 57) followed by identifying their antihypertensive effects in vivo in experimental models of hypertension such as spontaneously hypertensive rats (SHR), angiotensin hypertension, Ren-2 transgenic rats and deoxycorticosterone acetate (DOCA)-salt hypertension(41, 50-51, 53, 67, 107, 123, 131) . Inhibition of sEH also reduced the elevation of blood pressure in high fat diet fed rats and mice and other experimental models of metabolic syndrome (43, 104). Clinically, the sEH inhibitor, AR9281 has recently completed a phase IIA clinical trial in patients with mild to moderate hypertension and impaired glucose tolerance (14).
In heart failure, Ephx2 has been identified as a heart failure susceptible gene in SHR (16, 35) . Increased EETs levels, via over-expression of CYP2J, pharmacological inhibition of sEH, or Ephx2 gene deletion, improved post-ischemic left ventricular developed pressure recovery and reduced the infarct size after ischemia/reperfusion injury (5-6, 13). Similar results were obtained in mice and dogs with coronary artery ligation followed by reperfusion as Ephx2 gene deletion or inhibition of sEH also reduced the infarct size (39, 71). Inhibition of sEH provides anti-hypertrophic effects in hypertensive animal models of cardiac hypertrophy such as in DOCA-salt hypertension, stroke-prone SHR and angiotensin II induced hypertension (3, 59, 63 ) and prevents the development of left ventricular hypertrophy in mice with pressure overloadinduced myocardial failure (118) . Ephx2 gene deletion also protected myocardium from angiotensin II-induced cardiac arrhythmia and pressure overload-induced heart failure (2-3).
However, the clinical use of sEH inhibition or EETs analogs for treatment of heart failure could be limited by the recent observation that Ephx2 gene deletion or sEH inhibition delayed blood pressure recovery and resulted in higher mortality rate in transient cardiac arrest/resuscitation mice model (44).
In stroke, chronic treatment with sEH inhibitor decreased cerebral infarct size after middle cerebral artery occlusion in stroke-prone SHR via improving vascular function and protecting the neurons from cell death independent on blood pressure lowering effects (101) (102) .
Similarly, Ephx2 gene deletion decreased infarct size following a cerebral ischemia (101) .
Inhibition of sEH also exerted an angiogenic effect in stoke prone SHR as it increased microvascular densities and cerebral artery compliance (21).
In metabolic syndrome and diabetes, CYP expression decreased and sEH increased in obese animal models (18, 115) and polymorphism of Ephx2 gene is associated with insulin resistance in type 2 diabetic patients (79). Studies suggest that EETs is involved in glucose homeostasis and improving insulin signaling during obesity (65, 125). For example, overexpression of CYP2J3 epoxygenase improved insulin resistance in diabetic db/db mice and in fructose-induced insulin resistant rats (119) and inhibition of sEH or Ephx2 gene deletion decreased glucose levels and improved insulin signal and sensitivity in high fat diet fed mice (65). Inhibition of sEH also decreased blood glucose and improved endothelial function in db/db obese mice (125) . In heme oxygenase-2 (HO-2) knock-out mice, another model of obesity with decreased EETs levels, a dual-activity EET agonist/sEH inhibitor improved phenotypic characteristics of metabolic syndrome as it reduced body weight, visceral fat, and blood glucose together with increase EETs levels (104) . In type 1 diabetic animal model, Ephx2 gene deletion or pharmacological inhibition of sEH has recently shown to reduce blood glucose in streptozotocin-induced diabetes (64).
In atherosclerosis, polymorphism in Ephx2 is also linked to incidence of atherosclerosis (58) and inhibition of sEH reduced inflammation and prevented the development of atherosclerotic plaques in apoE-knock-out mice model of atherosclerosis suggesting that increased EETs levels may have therapeutic potential for treatment of hyperlipidemia (111, 126) .
Reno-protective effects of EETs in CVD
Inhibition of sEH has been shown to protect kidney from end-organ damage in angiotensin II hypertensive rats as it decreased glomerular and tubular collagen expression and vascular hypertrophy and reduced albuminuria (50, 131) . Inhibition of sEH also attenuated afferent arteriolar diameter responses to angiotensin II in isolated kidneys from chronic angiotensin II hypertensive rats (131) . Moreover, urinary albumin excretion was decreased and macrophage infiltration was reduced by sEH inhibitor treatment in angiotensin II-salt sensitive hypertension (50) . Inhibition of sEH also increased urinary salt and water excretion and decreased renal vascular resistance in angiotensin II infused mice (51) . The reno-protective effect of sEH inhibition was quite obvious either during the progression of hypertension or after hypertension was established (49-51, 131). In Goldblatt two-kidney, one-clip (2K1C) hypertensive rats, inhibition of sEH decreased blood pressure and sodium excretion together with improved renal blood flow and glomerular filtration rate (GFR) (107, 114) . Inhibition of sEH also provides renal protection in stroke-prone SHR as it decreased blood pressure, renal arteriolar hypertrophy, and proteinuria (59). Ephx2 gene deletion or pharmacological inhibition of sEH also decreased blood pressure and attenuated renal inflammation and glomerular injury in 
Reno-protective mechanisms of EETs in cardiovascular diseases
The potential reno-protective mechanisms of EETs are summarized in figure 3 and as follows;
A-EETs hypotensive and hypoglycemic effects
EETs improve renal function and protect the kidney from renal inflammation and injury associated with the progression of CVD as they increase renal blood flow, GFR and sodium excretion and decrease renal vascular resistance (47, [105] [106] . Previous studies suggest that the antihypertensive effect of EETs mediates their reno-protective effects as inhibition of sEH lowered blood pressure together with reduced renal injury in hypertensive and metabolic syndrome animal models (43, 50, 131). However, the antihypertensive effect of sEH inhibitors is not the sole reno-protective mechanism as inhibition of sEH maintained renal protection in hypertensive diabetic Goto-Kakizaki independent on blood pressure lowering effects (80).
Moreover, the Ephx2 deletion demonstrated variable results on blood pressure in hypertensive and diabetic mice models (23, 67, 103, 127) though these mice exhibited reduced renal injury when diabetes was experimentally induced despite blood pressure lowering effects (23).
Similarly, Ephx2 deletion or sEH inhibitors have also been shown to reduce blood glucose and enhance glucose utilization via increased insulin release, reduced β-cell apoptosis, and decreased insulin resistance in obese and diabetic mice (64-65). The hypoglycemic effect of sEH inhibition could be also considered a potential reno-protective mechanism against diabeticinduced renal injury; however, Ephx2 gene deletion or pharmacological inhibition of sEH failed to lower blood glucose in steptozotocin-induced diabetic mice though it provided renal protection against diabetic-induced renal injury (23). Collectively, the hypotensive and hypoglycemic effects of sEH inhibition could not completely explain the reno-protective effects of EETs in CVD and additional reno-protective mechanisms of EETs in CVD are yet to be explored.
B-EETs anti-inflammatory effects
It well known that inflammatory cytokines are key components in end-organ damage associated with CVD ( WT mice subjected to 45 minutes ischemia followed by 4 hours perfusion as well as in the left contralateral control (figure 4). Accordingly, the anti-inflammatory and anti-apoptotic effects of EETs could be a potential reno-protective mechanism against CVD-induced renal injury.
C-EETs-PPAR interaction
Peroxisome proliferator-activated receptor-alpha (PPAR-α) activator is involved in regulating fatty acid metabolism and attenuates vascular smooth muscle cell proliferation (40, 92). PPAR-α agonists have been shown to reduce renal injury, oxidative stress and inflammation during CVD with or without blood pressure lowering effects (37, 42-43). EETs have been shown to activate PPAR-α (30, 75) and inhibition of sEH also activates PPAR-α and inhibits cyclin D1 (29, 76). Accordingly, the ability of sEH inhibitors to activate PPAR-α could be beneficial in protecting kidney from end-organ damage associated with patients with hyperlipidemia, diabetes and hypertension. EETs also increase PPAR-γ transcription activity where PPAR-γ agonists are insulin sensitizer and are key elements in inhibiting NFκB-induced inflammation (62). Current commercial available PPAR-γ agonists for treatment of diabetes have unwanted fluid retaining effect, which is detrimental to patients with CVD especially those with heart failure. Accordingly, using sEH inhibitor with or without PPAR-γ agonist could provide a new avenue for treatment of cardiometabolic syndrome and protect kidney for ESRD because EETs diuretic and natriuretic effects could lessen the fluid retaining properties of PPAR-γ agonist.
D-EETs-heme oxygenase relationship
Heme oxygenase (HO) is the primary pathway for heme metabolism generating biliverdin, iron, and CO and biliverdin which is further metabolized to bilirubin (1, 110) . Two isoenzymes of HO are well known; HO-1 and HO-2. HO-1 is induced in response to many pathophysiological changes in CVD such as hypoxia, oxidative stress, ischemia, and increased cytokines whereas HO-2 is the constitutive isoenzyme that accounts for most HO activity in normal healthy state (1, 110) . Induction of HO-1 provides protective effects via the dissipation of the pro-oxidant heme and the generation of the antioxidant, anti-inflammatory and anti-apoptotic metabolites (1, 110) . It is well known that HO-1 induction could protect kidney from end-organ 
